chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dysgeusia, Hypoaesthesia oral, Paraesthesia oral
Clinical narrative: my lips and the sides of my tongue felt tingly and somewhat numb...no swelling; my lips and the sides of my tongue felt tingly and somewhat numb...no swelling; my lips and the sides of my tongue felt tingly and somewhat numb...no swelling; metallic taste in mouth; This is a spontaneous report received from a contactable consumer (Patient). A 68-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number: EN8203) via an unspecified route of administration, administered in left arm, on 02Mar2021 at 01:45 PM (at the age of 68-years-old), as a single dose for COVID-19 immunization. The patient medical history included thyroid disease, and had known allergies which included Gluten, hydrocodone, penicillin, sulfa, clindamycin, ACE inhibitors, Batrim, Azithromycin. The patient did not receive any other vaccine within four weeks of vaccination. Patient did not have COVID-19 prior vaccination. Concomitant medications included Synthroid, Cytomel, HCTZ, Olmesartan, Vit D. On 02Mar2021 at 02:00 PM (within the first 15 minutes of 30 minute required post vaccine wait time), patient lips and the sides of tongue felt tingly and somewhat numb but no swelling. She also noticed a metallic taste in mouth around the same time. The strange taste quickly resolved with drinking warm coffee and lips/mouth slight tingling and numbness issue stayed the same beyond wait time. Total time around 45-minutes to an hour. Patient did not receive any treatment for events. The patient was not tested for Covid post vaccination. The outcome of all the events was reported as recovered.  No follow-up attempts are possible. No further information is expected.
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Heart rate increased, Hypoaesthesia, Hypoaesthesia oral, Paraesthesia
Clinical narrative: swelling and numbness in my face and lips; swelling and numbness in my face and lips; swelling and numbness in my face and lips; swelling and numbness in my face and lips; Racing heartbeat; I have degenerative disc disease and arthritis. After 1 day those symptoms have almost disappeared; This is a spontaneous report from a contactable consumer, reporting for himself. A 61-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number unknown) via an unspecified route of administration in left arm on 01Mar2021 11:15AM (at the age of 61-year-old) at single dose for COVID-19 immunisation. The patient did not receive any other vaccine in four weeks. Relevant medical history included asthma, arthritis, degenerative disc disease and type 2 diabetes. The patient had latex allergy. He did not have COVID prior to vaccination. Concomitant medications were not reported. About 30 minutes after injection, the patient started to get some swelling and numbness in face and lips, racing heartbeat. Breathing was normal. As of 05Mar2021 he was still having these symptoms. On a positive note the patient had degenerative disc disease and arthritis. After 1 day those symptoms have almost disappeared. No treatment was received. The patient was not tested for COVID after vaccination. The events were non-serious and not resolved.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Heart rate increased, Hypoaesthesia, Hypoaesthesia oral, Lip swelling, Swelling face
Clinical narrative: swelling and numbness in my face and lips; swelling and numbness in my face and lips; swelling and numbness in my face and lips; swelling and numbness in my face and lips; Racing heartbeat; I have degenerative disc disease and arthritis. After 1 day those symptoms have almost disappeared; This is a spontaneous report from a contactable consumer, reporting for himself. A 61-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number unknown) via an unspecified route of administration in left arm on 01Mar2021 11:15AM (at the age of 61-year-old) at single dose for COVID-19 immunisation. The patient did not receive any other vaccine in four weeks. Relevant medical history included asthma, arthritis, degenerative disc disease and type 2 diabetes. The patient had latex allergy. He did not have COVID prior to vaccination. Concomitant medications were not reported. About 30 minutes after injection, the patient started to get some swelling and numbness in face and lips, racing heartbeat. Breathing was normal. As of 05Mar2021 he was still having these symptoms. On a positive note the patient had degenerative disc disease and arthritis. After 1 day those symptoms have almost disappeared. No treatment was received. The patient was not tested for COVID after vaccination. The events were non-serious and not resolved.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Therapeutic response unexpected
Clinical narrative: swelling and numbness in my face and lips; swelling and numbness in my face and lips; swelling and numbness in my face and lips; swelling and numbness in my face and lips; Racing heartbeat; I have degenerative disc disease and arthritis. After 1 day those symptoms have almost disappeared; This is a spontaneous report from a contactable consumer, reporting for himself. A 61-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number unknown) via an unspecified route of administration in left arm on 01Mar2021 11:15AM (at the age of 61-year-old) at single dose for COVID-19 immunisation. The patient did not receive any other vaccine in four weeks. Relevant medical history included asthma, arthritis, degenerative disc disease and type 2 diabetes. The patient had latex allergy. He did not have COVID prior to vaccination. Concomitant medications were not reported. About 30 minutes after injection, the patient started to get some swelling and numbness in face and lips, racing heartbeat. Breathing was normal. As of 05Mar2021 he was still having these symptoms. On a positive note the patient had degenerative disc disease and arthritis. After 1 day those symptoms have almost disappeared. No treatment was received. The patient was not tested for COVID after vaccination. The events were non-serious and not resolved.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 29.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dyspnoea, Feeling cold, Palpitations
Clinical narrative: Woke up around 4:30 AM short of breath, feeling somewhat queasy, cold forehead. Checked pulse, heart was racing, around 120 BPM.; Woke up around 4:30 AM short of breath, feeling somewhat queasy, cold forehead. Checked pulse, heart was racing, around 120 BPM.; Woke up around 4:30 AM short of breath, feeling somewhat queasy, cold forehead. Checked pulse, heart was racing, around 120 BPM.; Woke up around 4:30 AM short of breath, feeling somewhat queasy, cold forehead. Checked pulse, heart was racing, around 120 BPM.; Stood up, walked to next room, heart rate increased to around 160, hands shaking, cold hands and forehead; Stood up, walked to next room, heart rate increased to around 160, hands shaking, cold hands and forehead; This is a spontaneous report from a contactable consumer (patient). A 29-year-old non-pregnant female patient received BNT162B2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number: EN6198, Expiration date was not reported), via an unspecified route of administration, administered in right arm on 05Mar2021 at 16:15 hours as 1st dose, single (at the age of 29-years-old) for covid-19 immunisation. Medical history included known allergies: avocado gives stomach aches, depression/anxiety and vitamin D supplements. Patient had no other vaccine in four weeks. Concomitant medication(s) included sertraline hydrochloride (ZOLOFT) at a dose of 50 mg/day taken for depression/anxiety; vitamin D not otherwise specified (NOS) taken for vitamin D supplements. On 06Mar2021, the patient woke up around 4:30 AM and experienced short of breath, feeling somewhat queasy, cold forehead. Checked pulse, heart was racing, around 120 BPM. Stood up, walked to next room, heart rate increased to around 160, hands shaking, cold hands and forehead. Called family doctor, given advice to apply pressure to one side of neck and keep an eye on it for half an hour. Did slow breathing and followed advice; heart returned to normal rate within half an hour. Patient received no treatment for all the events. Prior to vaccination, the patient was not diagnosed with COVID-19; Since the vaccination, the patient not been tested for COVID-19. The outcome of all the events was recovered on 06Mar2021.  No follow-up attempts are possible. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dyspnoea, Heart rate, Nasopharyngitis, Nausea, Palpitations
Clinical narrative: Woke up around 4:30 AM short of breath, feeling somewhat queasy, cold forehead. Checked pulse, heart was racing, around 120 BPM.; Woke up around 4:30 AM short of breath, feeling somewhat queasy, cold forehead. Checked pulse, heart was racing, around 120 BPM.; Woke up around 4:30 AM short of breath, feeling somewhat queasy, cold forehead. Checked pulse, heart was racing, around 120 BPM.; Woke up around 4:30 AM short of breath, feeling somewhat queasy, cold forehead. Checked pulse, heart was racing, around 120 BPM.; Stood up, walked to next room, heart rate increased to around 160, hands shaking, cold hands and forehead; Stood up, walked to next room, heart rate increased to around 160, hands shaking, cold hands and forehead; This is a spontaneous report from a contactable consumer (patient). A 29-year-old non-pregnant female patient received BNT162B2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number: EN6198, Expiration date was not reported), via an unspecified route of administration, administered in right arm on 05Mar2021 at 16:15 hours as 1st dose, single (at the age of 29-years-old) for covid-19 immunisation. Medical history included known allergies: avocado gives stomach aches, depression/anxiety and vitamin D supplements. Patient had no other vaccine in four weeks. Concomitant medication(s) included sertraline hydrochloride (ZOLOFT) at a dose of 50 mg/day taken for depression/anxiety; vitamin D not otherwise specified (NOS) taken for vitamin D supplements. On 06Mar2021, the patient woke up around 4:30 AM and experienced short of breath, feeling somewhat queasy, cold forehead. Checked pulse, heart was racing, around 120 BPM. Stood up, walked to next room, heart rate increased to around 160, hands shaking, cold hands and forehead. Called family doctor, given advice to apply pressure to one side of neck and keep an eye on it for half an hour. Did slow breathing and followed advice; heart returned to normal rate within half an hour. Patient received no treatment for all the events. Prior to vaccination, the patient was not diagnosed with COVID-19; Since the vaccination, the patient not been tested for COVID-19. The outcome of all the events was recovered on 06Mar2021.  No follow-up attempts are possible. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Peripheral coldness, Tremor
Clinical narrative: Woke up around 4:30 AM short of breath, feeling somewhat queasy, cold forehead. Checked pulse, heart was racing, around 120 BPM.; Woke up around 4:30 AM short of breath, feeling somewhat queasy, cold forehead. Checked pulse, heart was racing, around 120 BPM.; Woke up around 4:30 AM short of breath, feeling somewhat queasy, cold forehead. Checked pulse, heart was racing, around 120 BPM.; Woke up around 4:30 AM short of breath, feeling somewhat queasy, cold forehead. Checked pulse, heart was racing, around 120 BPM.; Stood up, walked to next room, heart rate increased to around 160, hands shaking, cold hands and forehead; Stood up, walked to next room, heart rate increased to around 160, hands shaking, cold hands and forehead; This is a spontaneous report from a contactable consumer (patient). A 29-year-old non-pregnant female patient received BNT162B2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number: EN6198, Expiration date was not reported), via an unspecified route of administration, administered in right arm on 05Mar2021 at 16:15 hours as 1st dose, single (at the age of 29-years-old) for covid-19 immunisation. Medical history included known allergies: avocado gives stomach aches, depression/anxiety and vitamin D supplements. Patient had no other vaccine in four weeks. Concomitant medication(s) included sertraline hydrochloride (ZOLOFT) at a dose of 50 mg/day taken for depression/anxiety; vitamin D not otherwise specified (NOS) taken for vitamin D supplements. On 06Mar2021, the patient woke up around 4:30 AM and experienced short of breath, feeling somewhat queasy, cold forehead. Checked pulse, heart was racing, around 120 BPM. Stood up, walked to next room, heart rate increased to around 160, hands shaking, cold hands and forehead. Called family doctor, given advice to apply pressure to one side of neck and keep an eye on it for half an hour. Did slow breathing and followed advice; heart returned to normal rate within half an hour. Patient received no treatment for all the events. Prior to vaccination, the patient was not diagnosed with COVID-19; Since the vaccination, the patient not been tested for COVID-19. The outcome of all the events was recovered on 06Mar2021.  No follow-up attempts are possible. No further information is expected.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain upper, Arthralgia, Asthenia, Chills, Dizziness
Clinical narrative: night sweats; stomach aches; leg cramps; leg swelling (water retention); leg swelling (water retention); weakness; prickly skin; fever; chills; joint pain; slight cough; This is a spontaneous report from a contactable consumer (patient). A 71-year-old male patient received bnt162b2 (solution for injection, Lot Number: el926) via an unspecified route of administration, administered in Left arm on 09Feb2021 (at the age of 71-year-old) at 10:30 as 1st dose, single dose. The patient medical history and concomitant medications were not reported. The patient did not receive any vaccination in four weeks. On 09Feb2021, the patient experienced night sweats, stomach aches, leg cramps, leg swelling (water retention), weakness, prickly skin, fever, chills, joint pain and slight cough. The patient did not receive any treatment for events. The patient was not tested for covid prior vaccination but was post vaccination. The patient underwent lab tests which included nasal swab: negative on 01Mar2021. The patient received bnt162b2 (Lot number: en6199) on 02Mar2021 at 10:00 as 2nd dose, single dose for COVID-19 immunization. The outcome of events was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Malaise, Muscle spasms, Myalgia, Night sweats, Peripheral swelling
Clinical narrative: night sweats; stomach aches; leg cramps; leg swelling (water retention); leg swelling (water retention); weakness; prickly skin; fever; chills; joint pain; slight cough; This is a spontaneous report from a contactable consumer (patient). A 71-year-old male patient received bnt162b2 (solution for injection, Lot Number: el926) via an unspecified route of administration, administered in Left arm on 09Feb2021 (at the age of 71-year-old) at 10:30 as 1st dose, single dose. The patient medical history and concomitant medications were not reported. The patient did not receive any vaccination in four weeks. On 09Feb2021, the patient experienced night sweats, stomach aches, leg cramps, leg swelling (water retention), weakness, prickly skin, fever, chills, joint pain and slight cough. The patient did not receive any treatment for events. The patient was not tested for covid prior vaccination but was post vaccination. The patient underwent lab tests which included nasal swab: negative on 01Mar2021. The patient received bnt162b2 (Lot number: en6199) on 02Mar2021 at 10:00 as 2nd dose, single dose for COVID-19 immunization. The outcome of events was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pyrexia, SARS-CoV-2 antibody test negative, SARS-CoV-2 test negative
Clinical narrative: night sweats; stomach aches; leg cramps; leg swelling (water retention); leg swelling (water retention); weakness; prickly skin; fever; chills; joint pain; slight cough; This is a spontaneous report from a contactable consumer (patient). A 71-year-old male patient received bnt162b2 (solution for injection, Lot Number: el926) via an unspecified route of administration, administered in Left arm on 09Feb2021 (at the age of 71-year-old) at 10:30 as 1st dose, single dose. The patient medical history and concomitant medications were not reported. The patient did not receive any vaccination in four weeks. On 09Feb2021, the patient experienced night sweats, stomach aches, leg cramps, leg swelling (water retention), weakness, prickly skin, fever, chills, joint pain and slight cough. The patient did not receive any treatment for events. The patient was not tested for covid prior vaccination but was post vaccination. The patient underwent lab tests which included nasal swab: negative on 01Mar2021. The patient received bnt162b2 (Lot number: en6199) on 02Mar2021 at 10:00 as 2nd dose, single dose for COVID-19 immunization. The outcome of events was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain upper, Arthralgia, Asthenia, Chills, Cough
Clinical narrative: night sweats; stomach aches; leg cramps; leg swelling (water retention); leg swelling (water retention); weakness; prickly skin; fever; chills; joint pain; slight cough; This is a spontaneous report from a contactable consumer (patient). A 71-year-old male patient received bnt162b2 (solution for injection, Lot Number: el926) via an unspecified route of administration, administered in Left arm on 09Feb2021 (at the age of 71-year-old) at 10:30 as 1st dose, single dose. The patient medical history and concomitant medications were not reported. The patient did not receive any vaccination in four weeks. On 09Feb2021, the patient experienced night sweats, stomach aches, leg cramps, leg swelling (water retention), weakness, prickly skin, fever, chills, joint pain and slight cough. The patient did not receive any treatment for events. The patient was not tested for covid prior vaccination but was post vaccination. The patient underwent lab tests which included nasal swab: negative on 01Mar2021. The patient received bnt162b2 (Lot number: en6199) on 02Mar2021 at 10:00 as 2nd dose, single dose for COVID-19 immunization. The outcome of events was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Fluid retention, Muscle spasms, Night sweats, Peripheral swelling, Pyrexia
Clinical narrative: night sweats; stomach aches; leg cramps; leg swelling (water retention); leg swelling (water retention); weakness; prickly skin; fever; chills; joint pain; slight cough; This is a spontaneous report from a contactable consumer (patient). A 71-year-old male patient received bnt162b2 (solution for injection, Lot Number: el926) via an unspecified route of administration, administered in Left arm on 09Feb2021 (at the age of 71-year-old) at 10:30 as 1st dose, single dose. The patient medical history and concomitant medications were not reported. The patient did not receive any vaccination in four weeks. On 09Feb2021, the patient experienced night sweats, stomach aches, leg cramps, leg swelling (water retention), weakness, prickly skin, fever, chills, joint pain and slight cough. The patient did not receive any treatment for events. The patient was not tested for covid prior vaccination but was post vaccination. The patient underwent lab tests which included nasal swab: negative on 01Mar2021. The patient received bnt162b2 (Lot number: en6199) on 02Mar2021 at 10:00 as 2nd dose, single dose for COVID-19 immunization. The outcome of events was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Rash, SARS-CoV-2 test
Clinical narrative: night sweats; stomach aches; leg cramps; leg swelling (water retention); leg swelling (water retention); weakness; prickly skin; fever; chills; joint pain; slight cough; This is a spontaneous report from a contactable consumer (patient). A 71-year-old male patient received bnt162b2 (solution for injection, Lot Number: el926) via an unspecified route of administration, administered in Left arm on 09Feb2021 (at the age of 71-year-old) at 10:30 as 1st dose, single dose. The patient medical history and concomitant medications were not reported. The patient did not receive any vaccination in four weeks. On 09Feb2021, the patient experienced night sweats, stomach aches, leg cramps, leg swelling (water retention), weakness, prickly skin, fever, chills, joint pain and slight cough. The patient did not receive any treatment for events. The patient was not tested for covid prior vaccination but was post vaccination. The patient underwent lab tests which included nasal swab: negative on 01Mar2021. The patient received bnt162b2 (Lot number: en6199) on 02Mar2021 at 10:00 as 2nd dose, single dose for COVID-19 immunization. The outcome of events was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood lactate dehydrogenase, Full blood count, Lymphadenopathy, Metabolic function test, Pain
Clinical narrative: a palpable supraclavicular mass on my left collarbone; This is a spontaneous report from a contactable female consumer (Patient). A 31-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for Injection, Batch/Lot number: EL8982), via an unspecified route of administration, administered in arm left on 15Jan2021 (at the age of 31-years-old) as single dose for COVID-19 immunization. The patient medical history included polycystic ovarian syndrome, shortness of breath, heart palpitations, vitamin D deficiency, seasonal allergies, allergy to horse serum and cats. The patient received unspecified concomitant medications. The patient received other vaccines prior to the COVID vaccine within 4 weeks. Prior to vaccination, the patient was not diagnosed with COVID-19. On an unspecified date in Jan2021 (10-days after receiving first dose COVID-19 vaccine), patient experienced a palpable supraclavicular mass on my left collarbone. Patient had reported to PCP, he ordered ultrasound and LDH/CBC/CMP labs. Then followed up with ENT Head/Neck Specialist for further follow-up. Mass varied in prominence over about 6 weeks and got worse a few days after 2nd injection (bigger and more uncomfortable). Now much smaller and less prominent but still noticeable upon examination. The patient did not receive any treatment for the events. Patient had doctor or other healthcare professional office/clinic visit for the event. The patient had not tested for COVID-19 post vaccination. The outcome of the event was recovering.  No follow-up attempts are possible. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Ultrasound scan
Clinical narrative: a palpable supraclavicular mass on my left collarbone; This is a spontaneous report from a contactable female consumer (Patient). A 31-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for Injection, Batch/Lot number: EL8982), via an unspecified route of administration, administered in arm left on 15Jan2021 (at the age of 31-years-old) as single dose for COVID-19 immunization. The patient medical history included polycystic ovarian syndrome, shortness of breath, heart palpitations, vitamin D deficiency, seasonal allergies, allergy to horse serum and cats. The patient received unspecified concomitant medications. The patient received other vaccines prior to the COVID vaccine within 4 weeks. Prior to vaccination, the patient was not diagnosed with COVID-19. On an unspecified date in Jan2021 (10-days after receiving first dose COVID-19 vaccine), patient experienced a palpable supraclavicular mass on my left collarbone. Patient had reported to PCP, he ordered ultrasound and LDH/CBC/CMP labs. Then followed up with ENT Head/Neck Specialist for further follow-up. Mass varied in prominence over about 6 weeks and got worse a few days after 2nd injection (bigger and more uncomfortable). Now much smaller and less prominent but still noticeable upon examination. The patient did not receive any treatment for the events. Patient had doctor or other healthcare professional office/clinic visit for the event. The patient had not tested for COVID-19 post vaccination. The outcome of the event was recovering.  No follow-up attempts are possible. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Lymphadenopathy
Clinical narrative: a palpable supraclavicular mass on my left collarbone; This is a spontaneous report from a contactable female consumer (Patient). A 31-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for Injection, Batch/Lot number: EL8982), via an unspecified route of administration, administered in arm left on 15Jan2021 (at the age of 31-years-old) as single dose for COVID-19 immunization. The patient medical history included polycystic ovarian syndrome, shortness of breath, heart palpitations, vitamin D deficiency, seasonal allergies, allergy to horse serum and cats. The patient received unspecified concomitant medications. The patient received other vaccines prior to the COVID vaccine within 4 weeks. Prior to vaccination, the patient was not diagnosed with COVID-19. On an unspecified date in Jan2021 (10-days after receiving first dose COVID-19 vaccine), patient experienced a palpable supraclavicular mass on my left collarbone. Patient had reported to PCP, he ordered ultrasound and LDH/CBC/CMP labs. Then followed up with ENT Head/Neck Specialist for further follow-up. Mass varied in prominence over about 6 weeks and got worse a few days after 2nd injection (bigger and more uncomfortable). Now much smaller and less prominent but still noticeable upon examination. The patient did not receive any treatment for the events. Patient had doctor or other healthcare professional office/clinic visit for the event. The patient had not tested for COVID-19 post vaccination. The outcome of the event was recovering.  No follow-up attempts are possible. No further information is expected.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Arthralgia, Back pain, Burning sensation, Chills, Cough
Clinical narrative: red and purple rash all over the body, from head to toe; persistent fever above 100.4 F (higher overnight); dry cough; Mild diarrhea; headaches; Severe lower-back; back-of-the legs pain that lasted for 48 - 60 hours; This is a spontaneous report from a contactable consumer (patient). A 71-years-old male patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: EL9267 and expiration date; not reported), via an unspecified route of administration, administered in Arm Left on 19Feb2021 09:30, as a SINGLE DOSE for covid-19 immunization. The patient's medical history included High blood pressure, complex regional pain syndrome(CRPD) and two stents put in around the heart on 22Feb2021. The patient had no known allergies. No other vaccine in four weeks. No covid prior vaccination. The patient's concomitant medications included losartan potassium 50mg and montelukast sodium 10mg. Historical vaccine included first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: EL9262 and expiration date not reported), via an unspecified route of administration, administered in Arm Left on 29Jan2021 03:30 PM, as a SINGLE DOSE for covid-19 immunisation. On 02Mar2021 19:30, the patient experienced red and purple rash all over the body from head to toe, persistent fever above 100.4 F (higher overnight), dry cough, mild diarrhea, headaches, severe lower-back and back-of-the legs pain that lasted for 48 - 60 hours. The patient underwent lab tests and procedures which included fever: above 100.4 Fahrenheit (higher overnight) on 02Mar2021 and Nasal Swab test: negative on 05Mar2021. The outcome of the events leg pain and severe lower-back were recovered on an unspecified date in 2021 and for all other events outcome was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Diarrhoea, Fatigue, Headache, Pain in extremity, Pruritus
Clinical narrative: red and purple rash all over the body, from head to toe; persistent fever above 100.4 F (higher overnight); dry cough; Mild diarrhea; headaches; Severe lower-back; back-of-the legs pain that lasted for 48 - 60 hours; This is a spontaneous report from a contactable consumer (patient). A 71-years-old male patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: EL9267 and expiration date; not reported), via an unspecified route of administration, administered in Arm Left on 19Feb2021 09:30, as a SINGLE DOSE for covid-19 immunization. The patient's medical history included High blood pressure, complex regional pain syndrome(CRPD) and two stents put in around the heart on 22Feb2021. The patient had no known allergies. No other vaccine in four weeks. No covid prior vaccination. The patient's concomitant medications included losartan potassium 50mg and montelukast sodium 10mg. Historical vaccine included first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: EL9262 and expiration date not reported), via an unspecified route of administration, administered in Arm Left on 29Jan2021 03:30 PM, as a SINGLE DOSE for covid-19 immunisation. On 02Mar2021 19:30, the patient experienced red and purple rash all over the body from head to toe, persistent fever above 100.4 F (higher overnight), dry cough, mild diarrhea, headaches, severe lower-back and back-of-the legs pain that lasted for 48 - 60 hours. The patient underwent lab tests and procedures which included fever: above 100.4 Fahrenheit (higher overnight) on 02Mar2021 and Nasal Swab test: negative on 05Mar2021. The outcome of the events leg pain and severe lower-back were recovered on an unspecified date in 2021 and for all other events outcome was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Pyrexia, Rash, Rash erythematous, Rash macular, SARS-CoV-2 test negative
Clinical narrative: red and purple rash all over the body, from head to toe; persistent fever above 100.4 F (higher overnight); dry cough; Mild diarrhea; headaches; Severe lower-back; back-of-the legs pain that lasted for 48 - 60 hours; This is a spontaneous report from a contactable consumer (patient). A 71-years-old male patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: EL9267 and expiration date; not reported), via an unspecified route of administration, administered in Arm Left on 19Feb2021 09:30, as a SINGLE DOSE for covid-19 immunization. The patient's medical history included High blood pressure, complex regional pain syndrome(CRPD) and two stents put in around the heart on 22Feb2021. The patient had no known allergies. No other vaccine in four weeks. No covid prior vaccination. The patient's concomitant medications included losartan potassium 50mg and montelukast sodium 10mg. Historical vaccine included first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: EL9262 and expiration date not reported), via an unspecified route of administration, administered in Arm Left on 29Jan2021 03:30 PM, as a SINGLE DOSE for covid-19 immunisation. On 02Mar2021 19:30, the patient experienced red and purple rash all over the body from head to toe, persistent fever above 100.4 F (higher overnight), dry cough, mild diarrhea, headaches, severe lower-back and back-of-the legs pain that lasted for 48 - 60 hours. The patient underwent lab tests and procedures which included fever: above 100.4 Fahrenheit (higher overnight) on 02Mar2021 and Nasal Swab test: negative on 05Mar2021. The outcome of the events leg pain and severe lower-back were recovered on an unspecified date in 2021 and for all other events outcome was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Skin discolouration, Skin irritation, Skin warm
Clinical narrative: red and purple rash all over the body, from head to toe; persistent fever above 100.4 F (higher overnight); dry cough; Mild diarrhea; headaches; Severe lower-back; back-of-the legs pain that lasted for 48 - 60 hours; This is a spontaneous report from a contactable consumer (patient). A 71-years-old male patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: EL9267 and expiration date; not reported), via an unspecified route of administration, administered in Arm Left on 19Feb2021 09:30, as a SINGLE DOSE for covid-19 immunization. The patient's medical history included High blood pressure, complex regional pain syndrome(CRPD) and two stents put in around the heart on 22Feb2021. The patient had no known allergies. No other vaccine in four weeks. No covid prior vaccination. The patient's concomitant medications included losartan potassium 50mg and montelukast sodium 10mg. Historical vaccine included first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: EL9262 and expiration date not reported), via an unspecified route of administration, administered in Arm Left on 29Jan2021 03:30 PM, as a SINGLE DOSE for covid-19 immunisation. On 02Mar2021 19:30, the patient experienced red and purple rash all over the body from head to toe, persistent fever above 100.4 F (higher overnight), dry cough, mild diarrhea, headaches, severe lower-back and back-of-the legs pain that lasted for 48 - 60 hours. The patient underwent lab tests and procedures which included fever: above 100.4 Fahrenheit (higher overnight) on 02Mar2021 and Nasal Swab test: negative on 05Mar2021. The outcome of the events leg pain and severe lower-back were recovered on an unspecified date in 2021 and for all other events outcome was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Back pain, Body temperature, Cough, Diarrhoea, Headache
Clinical narrative: red and purple rash all over the body, from head to toe; persistent fever above 100.4 F (higher overnight); dry cough; Mild diarrhea; headaches; Severe lower-back; back-of-the legs pain that lasted for 48 - 60 hours; This is a spontaneous report from a contactable consumer (patient). A 71-years-old male patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: EL9267 and expiration date; not reported), via an unspecified route of administration, administered in Arm Left on 19Feb2021 09:30, as a SINGLE DOSE for covid-19 immunization. The patient's medical history included High blood pressure, complex regional pain syndrome(CRPD) and two stents put in around the heart on 22Feb2021. The patient had no known allergies. No other vaccine in four weeks. No covid prior vaccination. The patient's concomitant medications included losartan potassium 50mg and montelukast sodium 10mg. Historical vaccine included first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: EL9262 and expiration date not reported), via an unspecified route of administration, administered in Arm Left on 29Jan2021 03:30 PM, as a SINGLE DOSE for covid-19 immunisation. On 02Mar2021 19:30, the patient experienced red and purple rash all over the body from head to toe, persistent fever above 100.4 F (higher overnight), dry cough, mild diarrhea, headaches, severe lower-back and back-of-the legs pain that lasted for 48 - 60 hours. The patient underwent lab tests and procedures which included fever: above 100.4 Fahrenheit (higher overnight) on 02Mar2021 and Nasal Swab test: negative on 05Mar2021. The outcome of the events leg pain and severe lower-back were recovered on an unspecified date in 2021 and for all other events outcome was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Pain in extremity, Pyrexia, Rash, SARS-CoV-2 test
Clinical narrative: red and purple rash all over the body, from head to toe; persistent fever above 100.4 F (higher overnight); dry cough; Mild diarrhea; headaches; Severe lower-back; back-of-the legs pain that lasted for 48 - 60 hours; This is a spontaneous report from a contactable consumer (patient). A 71-years-old male patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: EL9267 and expiration date; not reported), via an unspecified route of administration, administered in Arm Left on 19Feb2021 09:30, as a SINGLE DOSE for covid-19 immunization. The patient's medical history included High blood pressure, complex regional pain syndrome(CRPD) and two stents put in around the heart on 22Feb2021. The patient had no known allergies. No other vaccine in four weeks. No covid prior vaccination. The patient's concomitant medications included losartan potassium 50mg and montelukast sodium 10mg. Historical vaccine included first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: EL9262 and expiration date not reported), via an unspecified route of administration, administered in Arm Left on 29Jan2021 03:30 PM, as a SINGLE DOSE for covid-19 immunisation. On 02Mar2021 19:30, the patient experienced red and purple rash all over the body from head to toe, persistent fever above 100.4 F (higher overnight), dry cough, mild diarrhea, headaches, severe lower-back and back-of-the legs pain that lasted for 48 - 60 hours. The patient underwent lab tests and procedures which included fever: above 100.4 Fahrenheit (higher overnight) on 02Mar2021 and Nasal Swab test: negative on 05Mar2021. The outcome of the events leg pain and severe lower-back were recovered on an unspecified date in 2021 and for all other events outcome was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 65.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Headache, Heart rate increased
Clinical narrative: nausea; my heart started beating hard and fast; my heart started beating hard and fast; headache; This is a spontaneous report from a contactable consumer or other non hcp.  A 65-years-old non pregnant female patient received bnt162b2 (Pfizer-BioNTech Covid-19 mRNA Vaccine, Solution for injection, Batch/Lot Number: EN6205), via an unspecified route of administration, administered on left arm on 04Mar2021 (at 65-years age) 10:45 as 1ST DOSE, SINGLE for covid-19 immunisation. Medical history was none. The patient did not receive any other vaccines within 4 weeks. Prior to vaccination, patient was not diagnosed with COVID-19. Concomitant medications included Multivitamin, fexofenadine hydrochloride (ALLEGRA); curcuma longa (TURMERIC [CURCUMA LONGA]); vitamin b complex (B COMPLEX [VITAMIN B COMPLEX]) taken for an unspecified indication. The patient previously took celebrex and experienced drug hypersensitivity. On 04Mar2021 10:45, it was reported that within a minute or two of injection my heart started beating hard and fast. A headache in the forehead began simultaneously with some nausea. she removed mask, rolled down the window for fresh air. The feeling had lessened by end of 15 minutes. The headache and racing heart returned several times during the day, with last one around 5:30 pm. Patient checked BP around 2 pm and it was 130/75. Didn't have any problems overnight. It was now 7:12 am Friday and she was fine so far. The patient not sure whether she should take the second shot. The patient underwent lab tests and procedures which included blood pressure measurement was 130/75 on 04Mar2021. No treatment received for the events. The outcome of events was recovered on an 05Mar2021.  No follow-up attempts are possible. No further information is expected.
Age: 65.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood pressure measurement, Headache, Heart rate increased, Nausea, Palpitations
Clinical narrative: nausea; my heart started beating hard and fast; my heart started beating hard and fast; headache; This is a spontaneous report from a contactable consumer or other non hcp.  A 65-years-old non pregnant female patient received bnt162b2 (Pfizer-BioNTech Covid-19 mRNA Vaccine, Solution for injection, Batch/Lot Number: EN6205), via an unspecified route of administration, administered on left arm on 04Mar2021 (at 65-years age) 10:45 as 1ST DOSE, SINGLE for covid-19 immunisation. Medical history was none. The patient did not receive any other vaccines within 4 weeks. Prior to vaccination, patient was not diagnosed with COVID-19. Concomitant medications included Multivitamin, fexofenadine hydrochloride (ALLEGRA); curcuma longa (TURMERIC [CURCUMA LONGA]); vitamin b complex (B COMPLEX [VITAMIN B COMPLEX]) taken for an unspecified indication. The patient previously took celebrex and experienced drug hypersensitivity. On 04Mar2021 10:45, it was reported that within a minute or two of injection my heart started beating hard and fast. A headache in the forehead began simultaneously with some nausea. she removed mask, rolled down the window for fresh air. The feeling had lessened by end of 15 minutes. The headache and racing heart returned several times during the day, with last one around 5:30 pm. Patient checked BP around 2 pm and it was 130/75. Didn't have any problems overnight. It was now 7:12 am Friday and she was fine so far. The patient not sure whether she should take the second shot. The patient underwent lab tests and procedures which included blood pressure measurement was 130/75 on 04Mar2021. No treatment received for the events. The outcome of events was recovered on an 05Mar2021.  No follow-up attempts are possible. No further information is expected.
Age: 74.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pruritus, Rash
Clinical narrative: Full body rash; swelling; itching; This is a spontaneous report from a contactable consumer (patient). A 74-years-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: EM9810), via an unspecified route of administration, administered in left arm on 05Mar2021 11:45 as unknown, single dose for covid-19 immunisation. Medical history included asthma, high blood pressure, atrial fibrillation (AFib). There was no known drug allergies (NKDA). There were no concomitant medications (no other vaccine in four weeks). There was no covid prior vaccination and covid not tested post vaccination. On 06Mar2021 04:30, patient experienced full body rash, swelling and itching. Adverse event resulted in Doctor or other healthcare professional office/clinic visit. Treatment was given for adverse events prescribed methylprednisolone. The outcome of event was recovering.   No follow-up attempts are needed; no further information expected.
Age: 74.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pruritus, Rash, Swelling
Clinical narrative: Full body rash; swelling; itching; This is a spontaneous report from a contactable consumer (patient). A 74-years-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: EM9810), via an unspecified route of administration, administered in left arm on 05Mar2021 11:45 as unknown, single dose for covid-19 immunisation. Medical history included asthma, high blood pressure, atrial fibrillation (AFib). There was no known drug allergies (NKDA). There were no concomitant medications (no other vaccine in four weeks). There was no covid prior vaccination and covid not tested post vaccination. On 06Mar2021 04:30, patient experienced full body rash, swelling and itching. Adverse event resulted in Doctor or other healthcare professional office/clinic visit. Treatment was given for adverse events prescribed methylprednisolone. The outcome of event was recovering.   No follow-up attempts are needed; no further information expected.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Asthenia, Dizziness, Feeling hot, Nausea, Pain
Clinical narrative: Weakness; Dizziness; Rash; tiredness; headache; muscle pain; joint pain; fever; body aches; nausea; This is a spontaneous report from a contactable consumer or other non hcp. A 44-years-old non pregnant female patient received bnt162b2 (BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection), dose 1 via an unspecified route of administration, administered in Left arm on 02Mar2021 15:30 (Batch/Lot Number: EN6200, Expiration date: unknown) as 1st DOSE, SINGLE DOSE for covid-19 immunisation. Medical history included fibromyalgia from an unknown date, rubber sensitivity from an unknown date. Concomitant medications included armour thyroid, duloxetine hydrochloride (cymbalta), vitamin d, vitamin c [ascorbic acid]. The patient previously took codeine and experienced drug hypersensitivity. On 04Mar2021 08:00 am the patient experienced weakness, dizziness, rash, tiredness, headache, muscle pain, joint pain, body aches, nausea. Outcome of all the events was not recovered. No follow-up attempts are possible. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pyrexia, Rash
Clinical narrative: Weakness; Dizziness; Rash; tiredness; headache; muscle pain; joint pain; fever; body aches; nausea; This is a spontaneous report from a contactable consumer or other non hcp. A 44-years-old non pregnant female patient received bnt162b2 (BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection), dose 1 via an unspecified route of administration, administered in Left arm on 02Mar2021 15:30 (Batch/Lot Number: EN6200, Expiration date: unknown) as 1st DOSE, SINGLE DOSE for covid-19 immunisation. Medical history included fibromyalgia from an unknown date, rubber sensitivity from an unknown date. Concomitant medications included armour thyroid, duloxetine hydrochloride (cymbalta), vitamin d, vitamin c [ascorbic acid]. The patient previously took codeine and experienced drug hypersensitivity. On 04Mar2021 08:00 am the patient experienced weakness, dizziness, rash, tiredness, headache, muscle pain, joint pain, body aches, nausea. Outcome of all the events was not recovered. No follow-up attempts are possible. No further information is expected.